These in-vitro findings implicate TLR9 as a potential driver of NF-κB in the CLL microenvironment with the potential to increase CLL cell activation and migration, even in the presence of BTK and BCL2 inhibition. This evidence concerns the gene NFKB1 and B-cell chronic lymphocytic leukemia.